 |
 |
|
|
|
| Cabazitaxel |
 |
| 99.8%min(HPLC) |
 |
| 183133-96-2 |
 |
Cabazitaxel Increased Survival for Patients with Advanced Hormone-Refractory Prostate Cancer
|
 |
Cabazitaxel is a novel investigational taxane compound that may be active in
cell lines refractory to taxanes. Cabazitaxel has been shown to inhibit cell
division and tumor cell proliferation by binding to and stabilizing tubulin, a
protein in the microtubules of cells which provides a skeleton for maintaining
cell shape.
Cabazitaxel recently received fast track designation from the U.S. Food and
Drug Administration (FDA) - a process designed to expedite the review of drugs
being developed for serious diseases with the potential to address an unmet
medical need. The rolling submission has already started and allows for
completed sections of a New Drug Application to be submitted on an ongoing
basis.
|
| Industrial field |
pharmaceutical |
|
|
 |
|
|
|
|
|
 |
| There are no existing companies to distribute selected chemical product |
|
 |
|
|
|
